Oxaliplatin (eloxatin™) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Rontogianni, D. | en |
dc.contributor.author | Karavasilis, V. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Rontogianni, D. | en |
dc.creator | Karavasilis, V. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:52:38Z | |
dc.date.available | 2018-06-22T09:52:38Z | |
dc.date.issued | 2005 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41441 | |
dc.description.abstract | Therapeutic options for metastatic insular thyroid carcinoma (ITC) are very limited. We present the case of a 39-year-old woman with refractory metastatic ITC who responded to oxaliplatin plus irinotecan chemotherapy. She was initially diagnosed with a locally advanced and metastatic to lung ITC and underwent near-total thyroidectomy. After surgery she was treated and failed to respond first to radioiodine and subsequently to liposomal doxorubicin plus paclitaxel combination chemotherapy and was offered palliative external irradiation for metastases to bone and the brain. Eleven months postdiagnosis the patient became severely dyspnoic as a result of progression of lung metastases and elected to be treated with oxaliplatin plus irinotecan as a second-line chemotherapy. She experienced relief of her dyspnea shortly after treatment initiation and an objective response of her lung metastases was documented after the third course of treatment. Treatment continued for six cycles and tumor remission lasted for 5 months. Toxicity was mild. Confirmatory testing of oxaliplatin-irinotecan combination in case series or single cases of metastatic ITC is warranted. © Mary Ann Liebert, Inc. | en |
dc.language.iso | eng | en |
dc.source | Thyroid | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Doxorubicin | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Thyroid neoplasms | en |
dc.subject | Adult | en |
dc.subject | Female | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Paclitaxel | en |
dc.subject | Priority journal | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Drug efficacy | en |
dc.subject | Oxaliplatin | en |
dc.subject | Cancer staging | en |
dc.subject | Metastasis | en |
dc.subject | Neoplasm metastasis | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Bone metastasis | en |
dc.subject | Irinotecan | en |
dc.subject | Platinum complex | en |
dc.subject | Immunohistochemistry | en |
dc.subject | Organoplatinum compounds | en |
dc.subject | Case report | en |
dc.subject | Pathology | en |
dc.subject | Brain metastasis | en |
dc.subject | Dyspnea | en |
dc.subject | Lung metastasis | en |
dc.subject | Lymphadenopathy | en |
dc.subject | Thorax radiography | en |
dc.subject | Lactate dehydrogenase | en |
dc.subject | Drug derivative | en |
dc.subject | Cancer palliative therapy | en |
dc.subject | Carcinoembryonic antigen | en |
dc.subject | Calcitonin | en |
dc.subject | Camptothecin | en |
dc.subject | Cd56 antigen | en |
dc.subject | Cervical lymph node | en |
dc.subject | Chromogranin | en |
dc.subject | Radioactive iodine | en |
dc.subject | Synaptophysin | en |
dc.subject | Thyroglobulin | en |
dc.subject | Thyroid carcinoma | en |
dc.subject | Thyroid tumor | en |
dc.subject | Thyroidectomy | en |
dc.subject | Thyrotropin | en |
dc.subject | Tumor regression | en |
dc.title | Oxaliplatin (eloxatin™) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1089/thy.2005.15.614 | |
dc.description.volume | 15 | |
dc.description.issue | 6 | |
dc.description.startingpage | 614 | |
dc.description.endingpage | 617 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Karavasilis, V. [0000-0002-5806-9399] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-5806-9399 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |